CD52 Specific Neutra™ Antibody Products

Product list

The Campath-1 antigen (CD52) is a glycoprotein with a molecular weight ranging between 21 and 28 kDa, which is widely expressed across mature lymphocytes, NK cells, monocytes, and dendritic cells, among other immune cells, and is anchored on glycosylphosphatidylinositol. CD52 is a non-regulatory membrane glycoprotein capable of activating T cells and modulating immune responses. Monoclonal antibodies targeting CD52 serve as effective and potent interventions in clinical settings for transplant patients.

Its Gene ID: 1043, UniProtKB ID: P31358, and OMIM ID: 114280.

CD52 Biology

Principal investigations on CD52 function and pathways concentrate on regulatory T cells. CD52 can exploit the TCR signal transduction mechanisms to promote T cell activation and downstream signaling. Knockout experiments have revealed that this process is reliant on the expression of CD45 and TCR, proffering co-stimulatory signals for T cell proliferation and activation.

Related studies have also uncovered the dichotomy of CD52 signals. Soluble CD52 molecules can interact reciprocally with Siglec-10 on the surface of T cells, significantly inhibiting T cell activation, thereby regulating T cell activation.

Fig.1 CD52 and soluble CD52. (Samten, 2012) Fig.1 CD52 and soluble CD52.¹

CD52 Therapeutics

Despite limited comprehension of the physiological pathways and pathophysiological significance of CD52, targeted antibody strategies are considered promising, feasible therapeutic interventions.

Anti-CD52 Monoclonal Antibodies

Monoclonal antibodies against CD52 have been subjected to extensive research and have found widespread clinical application as interventional and adjunct treatment strategies for diseases such as lymphocytic leukemia, organ transplantation, and multiple sclerosis.

CD52 and Tumor Microenvironment

Breast cancer oncology screenings have provided evidence that CD52 may contribute to preserving the immune privilege of the TME. This finding implies the potential of CD52 as an intervention target or prognostic marker for breast cancer.

Fig.2 CD52 signaling. (Zhao, et al., 2017) Fig.2 CD52 signaling.²

At Creative Biolabs, our goal is to provide our clientele with the highest quality CD52-related products and services to facilitate their successful research and applications pertaining to CD52. We cordially invite you to explore our neutralizing antibody and recombinant antibody technology platforms, with which we're confident you can propel your biological research to new heights.

REFERENCES

Samten. " CD52 as both a marker and an effector molecule of T cells with regulatory action: Identification of novel regulatory T cells." Cellular and Molecular Immunology 10 (2013): 456-458.
Zhao, Su, et al. " The immunological function of CD52 and its targeting in organ transplantation." Inflammation Research B (2017).

Show More Close